Welcome to our dedicated page for Brainstorm Cell Therapeutics I news (Ticker: BCLI), a resource for investors and traders seeking the latest updates and insights on Brainstorm Cell Therapeutics I stock.
BrainStorm Cell Therapeutics Inc. (BCLI) generates a steady flow of news centered on its NurOwn® autologous stem cell platform for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Company press releases highlight clinical milestones, regulatory interactions, financing developments, and scientific presentations that shape the outlook for its lead investigational therapy.
News coverage frequently focuses on clinical trial progress for NurOwn, including the completed Phase 3 ALS study and preparations for the Phase 3b ENDURANCE trial under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration. Updates describe FDA clearance to initiate the Phase 3b trial, submission of an IND amendment, listing of the study on ClinicalTrials.gov, and operational steps such as site activation and manufacturing readiness.
Investors and observers will also find data-driven announcements, such as survival results from BrainStorm’s Expanded Access Program in ALS and pharmacogenomic and biomarker analyses presented at scientific meetings. These releases detail how NurOwn-treated cohorts performed relative to published ALS survival estimates and discuss factors like the UNC13A genotype and cerebrospinal fluid biomarker pathways.
Additional news items cover regulatory and community developments, including the FDA’s consideration of a Citizen Petition requesting renewed review of NurOwn data, as well as BrainStorm’s engagement with the ALS community. Financial results and capital-raising activities are reported through quarterly earnings releases and 8-K filings, alongside information about promissory and convertible promissory notes.
Stock Titan’s BCLI news page aggregates these company-issued updates and related coverage, allowing readers to follow clinical, regulatory, scientific, and financing events that may influence BrainStorm’s development trajectory. For those tracking BCLI, this page offers a single location to review the latest disclosed information on NurOwn, ALS and MS programs, manufacturing partnerships, and listing status changes.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced the completion of all dosing in its Phase 2 clinical trial for NurOwn®, a treatment for progressive multiple sclerosis (MS). Conducted at five sites in the U.S., this trial represents a significant milestone for the company. CEO Chaim Lebovits expressed gratitude to the trial participants and investigators, emphasizing the potential of NurOwn to provide therapeutic options for MS patients. Top-line results are expected by the end of Q1 2021, which may influence further development and market acceptance of NurOwn.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has initiated an Expanded Access Program (EAP) for its autologous MSC-NTF cells, branded as NurOwn®, for ALS patients who participated in a recent Phase 3 clinical trial. Developed in collaboration with the FDA, the EAP allows select trial participants to access the investigational treatment. The initial focus will be on ALS patients less severely affected, based on the Revised ALS Functional Rating Scale. The EAP highlights the urgency recognized by BrainStorm and the ALS community for immediate treatment options.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced that results from the Phase 3 trial of NurOwn® treatment for ALS will be presented at the 31st International Symposium on ALS/MND on December 9-11, 2020. The trial involved 189 patients and assessed the safety and efficacy of NurOwn®. The company aims to increase awareness and discuss regulatory pathways for the treatment. Key presenters include Ralph Kern and Merit Cudkowicz, highlighting the importance of the trial's biomarker outcomes for ALS treatment response. The company is also exploring further clinical opportunities.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced results from its Phase 3 trial of NurOwn® for ALS. The therapy was generally well tolerated, showing a numerical improvement over placebo in key efficacy endpoints, although not statistically significant. In a subgroup of patients with early disease, NurOwn demonstrated a meaningful treatment response. Biomarker analysis indicated positive neurotrophic factor effects correlated with treatment. The company is in discussions with the FDA regarding potential approval pathways.
BrainStorm Cell Therapeutics (BCLI) has partnered with Rapid Reshore & Development (RR&D) to establish a new manufacturing facility for its cell therapy NurOwn in the U.S. This facility aims to support the production of treatments for neurodegenerative diseases like ALS and MS. The site selection and design process will begin immediately, with a facility size of approximately 50,000 square feet, expandable to 100,000 square feet. This expansion is crucial for preparing for potential regulatory approvals and enhancing production capabilities.
Catalent and BrainStorm Cell Therapeutics have announced a collaboration to manufacture NurOwn®, BrainStorm's cellular therapy for amyotrophic lateral sclerosis (ALS). This partnership will facilitate the transfer of the manufacturing process to Catalent's new facility in Houston, Texas, which spans 32,000 square feet. NurOwn has received Fast Track status from the U.S. FDA and Orphan Drug Status for ALS. Currently, BrainStorm is finalizing a Phase 3 clinical trial with 200 patients. The companies plan to expand their collaboration for commercial supply post-trial success.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced the presentation of a scientific poster on NurOwn® exosomes for treating ARDS at the NYSCF Conference on October 20, 2020. The study demonstrated significant improvements in lung function and reduced inflammation in a mouse model of ARDS, suggesting NurOwn exosomes may be a viable therapy for COVID-19 related lung complications. CEO Chaim Lebovits reaffirmed the company's commitment to advancing their therapeutic pipeline while preparing for the pivotal Phase 3 ALS clinical trial data release.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) reported its third quarter financial results for 2020, highlighting a net loss of $4.49 million, improved from $5.63 million in Q3 2019. The company has approximately $36 million in funding, with significant upcoming events including the NurOwn® Phase 3 trial data readout for ALS expected in November. Additionally, management updates include new appointments to enhance regulatory and commercial strategy, and plans for further clinical trials in progressive multiple sclerosis and Alzheimer's disease.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced that Stacy Lindborg, Ph.D., will present at the 2020 Cell & Gene Meeting on the Mesa, held virtually from October 12-16, 2020. The presentation is available on-demand for registered participants. The conference will showcase over 80 presentations by various companies highlighting advancements in cell therapy and gene therapy. BrainStorm’s NurOwn technology is focused on treating neurodegenerative diseases, including a Phase 3 trial for ALS and a Phase 2 trial for progressive MS, supported by FDA approvals.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) will hold a conference call on October 15, 2020, at 8:00 a.m. EDT to discuss third-quarter financial results for the period ending September 30, 2020, and provide a corporate update. The call will feature CEO Chaim Lebovits, alongside key executives who will answer shareholder questions. Participants can submit questions until October 13, 2020. The company is noted for its NurOwn technology, which targets neurodegenerative diseases and has several ongoing clinical trials.